目的 探討苦參凝膠聯(lián)合重組人干擾素α-2b凝膠治療宮頸高危型人乳頭瘤病毒感染的臨床療效。方法 收集無錫市婦幼保健院2023年1月—2024年1月收治的108例宮頸高危型人乳頭瘤病毒感染女性患者的病歷資料，根據(jù)臨床治療方案不同將患者分為對照組和治療組，各54例。對照組于月經(jīng)干凈3 d后使用重組人干擾素α-2b凝膠，1枚/次，1次/2 d。治療組在對照組基礎(chǔ)上于月經(jīng)干凈3 d后使用苦參凝膠，1枚/次，1次/d。兩組患者持續(xù)用藥3個月。比較兩組的臨床療效、人乳頭瘤病毒的病毒載量、高危型人乳頭瘤病毒感染轉(zhuǎn)陰率、陰道微生態(tài)情況、免疫功能指標(biāo)、血清免疫失衡因子。結(jié)果 對照組的總有效率為77.78%，治療組的總有效率為92.59%，組間比較差異顯著（P＜0.05）。治療后，治療組的人乳頭瘤病毒感染轉(zhuǎn)陰率為90.74%，高于對照組的人乳頭瘤病毒感染轉(zhuǎn)陰率75.93%，差異有統(tǒng)計學(xué)意義（P＜0.05）。兩組治療后人乳頭瘤病毒的病毒載量均顯著降低（P＜0.05），且治療組的人乳頭瘤病毒的病毒載量低于對照組（P＜0.05）。兩組治療后陰道分泌物pH值、Nugent評分均顯著降低（P＜0.05），且治療組陰道分泌物pH值、Nugent評分低于對照組（P＜0.05）。兩組治療后CD3⁺、CD4⁺均顯著升高，CD8⁺顯著降低（P＜0.05），且治療組CD3⁺、CD4⁺高于對照組，CD8⁺低于對照組（P＜0.05）。兩組治療后血清白細(xì)胞介素-2（IL-2）、白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）水平均顯著降低（P＜0.05），且治療組血清IL-2、IL-6、TNF-α水平低于對照組（P＜0.05）。結(jié)論 苦參凝膠聯(lián)合重組人干擾素α-2b凝膠治療宮頸高危型人乳頭瘤病毒感染的效果顯著，可促進(jìn)患者人乳頭瘤病毒感染轉(zhuǎn)陰，調(diào)節(jié)患者免疫功能和陰道微生態(tài)平衡。

Objective To explore the therapeutic effect of Kushen Gel combined with Recombinant Human Interferon α-2b Gel in treatment of high-risk cervical human papillomavirus infection. Methods The medical records of 108 female patients with high-risk cervical human papillomavirus infection admitted to Wuxi Maternal and Child Health Hospital from January 2023 to January 2024 were collected. According to different clinical treatment plans, the patients were divided into control group and treatment group, with 54 cases in each group. The control group used Recombinant Human Interferon α-2b Gel 3 d after menstruation, 1 piece/time, once every 2 d. The treatment group used Kushen Gel on the basis of the control group 3 d after menstruation, 1 piece/time, once daily. The patients in two groups were treated for 3 months. The clinical efficacy, viral load of human papillomavirus, seroconversion rate of high-risk human papillomavirus infection, vaginal microbiota, immune function indicators, and serum immune imbalance factors were compared between two groups. Results The total effective rate of the control group was 77.78%, while the total effective rate of the treatment group was 92.59%, and the difference was significant between two groups (P < 0.05). After treatment, the conversion rate of human papillomavirus infection in the treatment group was 90.74%, which was higher than 75.93% in the control group, and the difference was statistically significant (P < 0.05). The viral load of human papillomavirus in two groups was significantly decreased (P < 0.05), and the viral load of human papillomavirus in the treatment group was lower than that in the control group (P < 0.05). After treatment, the pH value and Nugent score of vaginal secretions in two groups significantly decreased (P < 0.05), and the pH value and Nugent score of vaginal secretions in the treatment group were lower than those in the control group (P < 0.05). After treatment, CD3⁺ and CD4⁺ in two groups significantly increased, while CD8⁺ significantly decreased (P < 0.05). CD3⁺ and CD4⁺ in the treatment group were higher than those in the control group, while CD8⁺ was lower than those in the control group (P < 0.05). After treatment, the serum levels of interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were significantly reduced in two groups (P < 0.05), and the serum levels of IL-2, IL-6, and TNF-α in the treatment group were lower than those in the control group (P < 0.05). Conclusion Kushen Gel combined with Recombinant Human Interferon α-2b Gel has a significant effect in treatment of high-risk cervical human papillomavirus infection, which can promote the negative transformation of human papillomavirus infection in patients, and regulate the immune function and vaginal microecological balance of patients.

R984

白求恩·醫(yī)學(xué)科學(xué)研究基金項目